FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

CORVESE RUSSEL J 		2. Issuer Name and Ticker or Trading Symbol

BioScrip, Inc. [ BIOS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP Mail Operations
(Last)          (First)          (Middle)

C/O BIOSCRIP, INC., 100 CLEARBROOK ROAD 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/16/2010
(Street)

ELMSFORD, NY 10523
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.0001 Par Value                  42838   (1) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   $6.65   6/16/2010     A      50000       6/16/2011   (2) 6/16/2020   Common Stock, $.0001 Par Value   50000   $0   50000   D    
Employee Stock Option (Right to Buy)   $12.20                    11/28/2002   (3) 11/28/2011   Common Stock, $.0001 Par Value   10000     10000   D    
Employee Stock Option (Right to Buy)   $7.95                    9/24/2004   (3) 9/24/2013   Common Stock, $.0001 Par Value   35000     35000   D    
Employee Stock Option (Right to Buy)   $6.00                    2/28/2007   (3) 6/30/2015   Common Stock, $.0001 Par Value   9200     9200   D    
Employee Stock Option (Right to Buy)   $2.47                    11/1/2007   (2) 11/1/2016   Common Stock, $.0001 Par Value   104858     104858   D    
Option To Purchase Common Stock   $6.52                    4/29/2009   (2) 4/29/2018   Common Stock, $.0001 Par Value   56250     56250   D    
Option To Purchase Common Stock   $2.73                    4/28/2010   (2) 4/28/2019   Common Stock, $.0001 Par Value   75000     75000   D    

Explanation of Responses:
( 1)  Does not include 175,010 shares of Common Stock held in the Corvese Irrevocable Trust - 1992, of which Mr. Corvese is a trustee. Mr. Corvese disclaims beneficial ownership of such shares of Common Stock.
( 2)  Vests and becomes exercisable in three equal annual installments commencing on the first anniversary of the date of grant.
( 3)  Fully Vested

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
CORVESE RUSSEL J
C/O BIOSCRIP, INC.
100 CLEARBROOK ROAD
ELMSFORD, NY 10523

SVP Mail Operations

Signatures
/s/ Russel J. Corvese 6/21/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2024 à Août 2024 Plus de graphiques de la Bourse BioPlus Acquisition
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Août 2023 à Août 2024 Plus de graphiques de la Bourse BioPlus Acquisition